New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Jade Biosciences

Contributing Author

Recent Articles by Jade Biosciences

Mar-06	Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update JBIO GlobeNewswire
Feb-11	Jade Biosciences to Participate in Upcoming Conferences JBIO GlobeNewswire
Jan-05	Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference JBIO -7.34% GlobeNewswire
Dec-15	Jade Biosciences Announces $45 Million Private Placement JBIO GlobeNewswire
Nov-13	Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update JBIO +10.54% JBIO GlobeNewswire
Nov-08	Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 JBIO GlobeNewswire
Nov-03	Jade Biosciences to Participate in Upcoming Conferences JBIO GlobeNewswire
Oct-17	Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 JBIO +6.72% JBIO GlobeNewswire
Oct-07	Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases JBIO GlobeNewswire
Oct-07	Jade Biosciences Announces $135 Million Private Placement JBIO GlobeNewswire
Sep-02	Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy JBIO GlobeNewswire
Aug-25	Jade Biosciences to Participate in Upcoming Conferences JBIO GlobeNewswire
Aug-13	Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update JBIO -7.64% JBIO GlobeNewswire
Jul-08	Jade Biosciences to Participate in Two Upcoming Investor Conferences JBIO GlobeNewswire
Jul-01	Jade Biosciences Appoints Brad Dahms as Chief Financial Officer JBIO +8.56% GlobeNewswire
Jun-09	Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy JBIO +7.23% GlobeNewswire
Jun-02	Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress JBIO GlobeNewswire
May-14	Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update JBIO -12.31% GlobeNewswire
May-13	Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference JBIO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)